Smythe W R, LeBel E, Bavaria J E, Kaiser L R, Albelda S M
Department of Surgery, University of Pennsylvania Medical Center, Philadelphia 19104, USA.
Cancer Metastasis Rev. 1995 Sep;14(3):229-39. doi: 10.1007/BF00690294.
Alteration of integrin expression in a number of different malignant diseases has been recognized, with a trend of downregulation of collagen-laminin binding integrin expression in epithelial tumor types noted. This study evaluated the expression of a panel of integrin subunits that included subunits that form receptors that bind to collagen and laminin (alpha 2, alpha 3, alpha 6 beta 4) and subunits that form receptors that bind to fibronectin and fibrinogen (alpha 5, alpha V, beta 3, beta 6) in 51 specimens of non-small cell carcinoma (NSCCA) of the lung by use of immunohistochemistry. Integrin expression was then correlated with histologic type (squamous vs. adenocarcinoma), absence or presence of hilar or mediastinal nodal metastasis at resection, and cellular differentiation (well or poorly differentiated). In general, downregulation of the collagen-laminin binding subunits was noted in tumor cells of the NSCCA specimens when compared to the progenitor normal bronchial epithelium. No differences were noted in integrin expression between squamous cell and adenocarcinoma or between node-positive or node-negative tumors. However, downregulation of the integrin subunit alpha 3 was noted to be significantly more common in poorly differentiated tumors (p = 0.02) and several of the other collagen-laminin binding subunits also appeared to be more downregulated in poorly differentiated tumors. No upregulation was seen in the alpha 5 subunit of the fibronectin receptor or the beta 3 subunit of the vitronectin receptor, however, approximately 50% of tumors showed upregulation of the beta 6 subunit, the great majority of these being well-differentiated, node-negative tumors. Downregulation of the collagen-laminin integrins may thus be associated with differentiation of NSCCA, but not metastasis, and may serve as an adjunctive prognostic marker of disease. The beta 6 subunit appears to be associated with malignant transformation, but may serve as a positive prognostic factor.
人们已经认识到多种不同恶性疾病中整合素表达的改变,其中上皮肿瘤类型中胶原-层粘连蛋白结合整合素表达呈下调趋势。本研究通过免疫组织化学方法评估了51例肺非小细胞癌(NSCCA)标本中一组整合素亚基的表达,这些亚基包括形成与胶原和层粘连蛋白结合的受体的亚基(α2、α3、α6β4)以及形成与纤连蛋白和纤维蛋白原结合的受体的亚基(α5、αV、β3、β6)。然后将整合素表达与组织学类型(鳞状细胞癌与腺癌)、切除时有无肺门或纵隔淋巴结转移以及细胞分化程度(高分化或低分化)进行关联分析。总体而言,与正常支气管上皮祖细胞相比,NSCCA标本的肿瘤细胞中胶原-层粘连蛋白结合亚基呈下调。鳞状细胞癌和腺癌之间或有淋巴结转移与无淋巴结转移的肿瘤之间在整合素表达上未发现差异。然而,整合素亚基α3的下调在低分化肿瘤中显著更常见(p = 0.02),并且其他几个胶原-层粘连蛋白结合亚基在低分化肿瘤中似乎也有更多下调。纤连蛋白受体的α5亚基或玻连蛋白受体的β3亚基未见上调,然而,约50%的肿瘤显示β6亚基上调,其中绝大多数为高分化、无淋巴结转移的肿瘤。因此,胶原-层粘连蛋白整合素的下调可能与NSCCA的分化有关,但与转移无关,并且可能作为疾病的辅助预后标志物。β6亚基似乎与恶性转化有关,但可能是一个阳性预后因素。